News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Begins Phase 1/2 Trial of Ponatinib in Japan



8/20/2012 9:40:07 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company’s investigational BCR-ABL inhibitor. The trial is being conducted in Japanese patients with chronic myeloid leukemia (CML) who have failed treatment with dasatinib or nilotinib or with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who have failed prior tyrosine kinase inhibitors. The trial is designed to establish the recommended dose for ponatinib and confirm its anti-leukemic activity in Japanese patients. The Company expects that this trial should provide the incremental clinical data needed for initial regulatory approval of ponatinib in Japan. Japan is the third largest CML market in the world with an annual incidence of 1,300 new patients reported in 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES